Management team

Craig Cook

Chief Executive Officer

Craig Cook MD is a medical doctor with an MBA from the London Business School and brings more than 20 years of experience in the international pharmaceutical and biotechnology sectors.  Dr Cook’s career has included increasingly senior roles in drug development and commercialization at major life science companies such as Eli Lilly, Johnson & Johnson, Novartis and EMD Serono, as well as entrepreneurial success in several healthcare initiatives. He was CEO of Midatech Pharma PLC a dual Nasdaq and AIM listed biotech company, before deciding to join Herantis Pharma in 2020.  He has worked across several therapeutic areas including neurology, immunology, and oncology.

Tone Kvåle

Chief Financial Officer

Tone Kvåle is a seasoned financial executive with 25 years of experience and a stong track record in the biotech and life sciences industry.  Most recently, she was CFO at Nordic Nanovector, a publicly listed company in Norway, for 7 years, and prior to that, she held CFO roles at NorDiag (publicly listed company), Kavli Holding, Dynal Biotech, as well as senior management positions at Invitrogen/Life Technologies, in US, now part of Thermo Fisher.  In these roles, she helped raise over EUR 200m in financing, was involved in several trade sales, M&A and licensing deals, and was responsible for financial reporting under various reporting standards including US GAAP and IFRS. She currently serves as director of the board and chair of the audit committee of Bonesupport AB, Sweden. Tone has a diploma in finance and administration from UiT The Arctic University of Norway, Harstad.

Antti Vuolanto

Chief Operating Officer

Antti Vuolanto, DSc, joined Herantis Pharma Plc in February 2018. He has vast experience in biological drug development, in-vitro diagnostics, and building start-up companies. Antti has in-depth knowledge of gene therapy-based drug development including scientific, CMC, and clinical trial expertise. Previously he served as COO at Valo Therapeutics, as Executive Vice President at Targovax ASA, and COO and co-founder at Oncos Therapeutics Ltd that merged with Targovax in 2015. He has also held senior management positions at other biotech companies. Dr. Vuolanto graduated as Doctor in Science in Technology at Aalto University, Finland, in 2004 in bioprocess engineering.

Henri Huttunen

Chief Scientific Officer

Henri Huttunen co-founded Herantis Pharma Plc. in 2008 and served as the company’s founding CEO for the first two years. Dr. Huttunen is currently the Chief Scientific Officer of Herantis. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School (USA). Dr. Huttunen has a PhD in biochemistry from the University of Helsinki and 25 years of experience in neuroscience research. While he was an adjunct professor, Dr. Huttunen lead an academic research group focusing on molecular mechanisms of neurodegenerative diseases at the Neuroscience Center, University of Helsinki.

Magnus Sjögren

Chief Medical Officer

Magnus Sjögren is Consultant Chief Medical Officer for Herantis Pharma since 2017. Dr. Sjögren will assume the role of Chief Medical Officer effective as of 1st of May 2021. He has extensive experience in drug development and translational research in several therapeutic areas, in particular in Neurology and Psychiatry, but also oncology and inflammation. He is a trained Psychiatrist with over 28 years of hands-on experience in clinical psychiatry. He is also Associate Professor at Gothenburg University since 2002 and a Lecturer at Copenhagen University since 2015, and the author of more than 135 scientific publications. Dr. Sjögren has held several senior executive and scientific positions: Chief Medical Officer at DiaGenic ASA; Vice President at UCB Pharma in Belgium and UK; Global Head of Translational Medicine in Schering-Plough; Senior Clinical Research Director in Organon NV and AstraZeneca.

Sigrid Booms

Head of Regulatory Affairs & Compliance

Sigrid Booms has served as Director of Clinical Development of Herantis since August 2011 and was promoted to Head of Regulatory Affairs & Compliance in December 2020. Mrs. Booms has more than 25 years of experience in global development of pharmaceuticals for human use, with previous positions in regulatory affairs at Orion Pharma and at a global clinical CRO as Director, Regulatory Affairs. During her career, she was involved in several drug development projects in the CNS therapeutic area and is currently the study director for the CDNF (protein) clinical development in Parkinson’s disease. Over the years she has become a specialist in regulatory aspects for nonclinical and early phase clinical development. Mrs. Booms holds a Licentiate in pharmacy from the University of Utrecht in the Netherlands.